227 related articles for article (PubMed ID: 25312396)
21. Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.
Alvarez EA; Brady WE; Walker JL; Rotmensch J; Zhou XC; Kendrick JE; Yamada SD; Schilder JM; Cohn DE; Harrison CR; Moore KN; Aghajanian C
Gynecol Oncol; 2013 Apr; 129(1):22-7. PubMed ID: 23262204
[TBL] [Abstract][Full Text] [Related]
22. A phase II trial of irinotecan in patients with advanced or recurrent endometrial cancer and correlation with biomarker analysis.
Nishio S; Shimokawa M; Tasaki K; Nasu H; Yoshimitsu T; Matsukuma K; Terada A; Tsuda N; Kawano K; Ushijima K
Gynecol Oncol; 2018 Sep; 150(3):432-437. PubMed ID: 30037491
[TBL] [Abstract][Full Text] [Related]
23. A phase 2 evaluation of irofulven as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group trial.
Schilder RJ; Blessing JA; Shahin MS; Miller DS; Tewari KS; Muller CY; Warshal DP; McMeekin S; Rotmensch J
Int J Gynecol Cancer; 2010 Oct; 20(7):1137-41. PubMed ID: 21495215
[TBL] [Abstract][Full Text] [Related]
24. Nintedanib, a novel triple angiokinase inhibitor for the treatment of non-small cell lung cancer.
Noonan S; Man Wong K; Jimeno A
Drugs Today (Barc); 2015 Jun; 51(6):357-66. PubMed ID: 26261849
[TBL] [Abstract][Full Text] [Related]
25. Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer.
Ledermann JA; Hackshaw A; Kaye S; Jayson G; Gabra H; McNeish I; Earl H; Perren T; Gore M; Persic M; Adams M; James L; Temple G; Merger M; Rustin G
J Clin Oncol; 2011 Oct; 29(28):3798-804. PubMed ID: 21859991
[TBL] [Abstract][Full Text] [Related]
26. Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I-type II study from the GINECO group.
Heudel PE; Fabbro M; Roemer-Becuwe C; Kaminsky MC; Arnaud A; Joly F; Roche-Forestier S; Meunier J; Foa C; You B; Priou F; Tazi Y; Floquet A; Selle F; Berton-Rigaud D; Lesoin A; Kalbacher E; Lortholary A; Favier L; Treilleux I; Ray-Coquard I
Br J Cancer; 2017 Jan; 116(3):303-309. PubMed ID: 28072765
[TBL] [Abstract][Full Text] [Related]
27. A phase II evaluation of weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma: a study by the Gynecologic Oncology Group.
Garcia AA; Blessing JA; Nolte S; Mannel RS;
Gynecol Oncol; 2008 Oct; 111(1):22-6. PubMed ID: 18675446
[TBL] [Abstract][Full Text] [Related]
28. Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial.
Hanna NH; Kaiser R; Sullivan RN; Aren OR; Ahn MJ; Tiangco B; Voccia I; Pawel JV; Kovcin V; Agulnik J; Gaschler-Markefski B; Barrueco J; Sikken P; Schloss C; Kim JH;
Lung Cancer; 2016 Dec; 102():65-73. PubMed ID: 27987591
[TBL] [Abstract][Full Text] [Related]
29. The addition of paclitaxel to doxorubicin and cisplatin and volume-directed radiation does not improve overall survival (OS) or long-term recurrence-free survival (RFS) in advanced endometrial cancer (EC): A randomized phase III NRG/Gynecologic Oncology Group (GOG) study.
Spirtos NM; Enserro D; Homesley HD; Gibbons SK; Cella D; Morris RT; DeGeest K; Lee RB; Miller DS
Gynecol Oncol; 2019 Jul; 154(1):13-21. PubMed ID: 31053405
[TBL] [Abstract][Full Text] [Related]
30. A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study.
Chan JK; Deng W; Higgins RV; Tewari KS; Bonebrake AJ; Hicks M; Gaillard S; Ramirez PT; Chafe W; Monk BJ; Aghajanian C
Gynecol Oncol; 2017 Sep; 146(3):554-559. PubMed ID: 28728751
[TBL] [Abstract][Full Text] [Related]
31. A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer.
Hall MR; Dehbi HM; Banerjee S; Lord R; Clamp A; Ledermann JA; Nicum S; Lilleywhite R; Bowen R; Michael A; Feeney A; Glasspool R; Hackshaw A; Rustin G
Gynecol Oncol; 2020 Dec; 159(3):692-698. PubMed ID: 33077258
[TBL] [Abstract][Full Text] [Related]
32. Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial.
Symonds RP; Gourley C; Davidson S; Carty K; McCartney E; Rai D; Banerjee S; Jackson D; Lord R; McCormack M; Hudson E; Reed N; Flubacher M; Jankowska P; Powell M; Dive C; West CML; Paul J
Lancet Oncol; 2015 Nov; 16(15):1515-1524. PubMed ID: 26474517
[TBL] [Abstract][Full Text] [Related]
33. Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology Group.
Scudder SA; Liu PY; Wilczynski SP; Smith HO; Jiang C; Hallum AV; Smith GB; Hannigan EV; Markman M; Alberts DS;
Gynecol Oncol; 2005 Mar; 96(3):610-5. PubMed ID: 15721401
[TBL] [Abstract][Full Text] [Related]
34. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study.
McMeekin DS; Filiaci VL; Thigpen JT; Gallion HH; Fleming GF; Rodgers WH;
Gynecol Oncol; 2007 Jul; 106(1):16-22. PubMed ID: 17574073
[TBL] [Abstract][Full Text] [Related]
35. Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.
Hensley ML; Sill MW; Scribner DR; Brown J; Debernardo RL; Hartenbach EM; McCourt CK; Bosscher JR; Gehrig PA
Gynecol Oncol; 2009 Dec; 115(3):460-5. PubMed ID: 19811811
[TBL] [Abstract][Full Text] [Related]
36. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
Modesitt SC; Sill M; Hoffman JS; Bender DP;
Gynecol Oncol; 2008 May; 109(2):182-6. PubMed ID: 18295319
[TBL] [Abstract][Full Text] [Related]
37. Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration.
Humber CE; Tierney JF; Symonds RP; Collingwood M; Kirwan J; Williams C; Green JA
Ann Oncol; 2007 Mar; 18(3):409-20. PubMed ID: 17150999
[TBL] [Abstract][Full Text] [Related]
38. A trial of outpatient paclitaxel and carboplatin for advanced, recurrent, and histologic high-risk endometrial carcinoma: preliminary report.
Price FV; Edwards RP; Kelley JL; Kunschner AJ; Hart LA
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-78-S15-82. PubMed ID: 9346228
[TBL] [Abstract][Full Text] [Related]
39. A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a gynecologic oncology group study.
Miller DS; Blessing JA; Lentz SS; Waggoner SE
Gynecol Oncol; 2002 Dec; 87(3):247-51. PubMed ID: 12468321
[TBL] [Abstract][Full Text] [Related]
40. A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial.
Moore KN; Sill MW; Tenney ME; Darus CJ; Griffin D; Werner TL; Rose PG; Behrens R
Gynecol Oncol; 2015 Sep; 138(3):513-8. PubMed ID: 26171911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
